Skip to main content

Table 1 Baseline characteristics of all included 483 patients with advanced pancreatic cancer

From: Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study

Characteristics BMI < 18.5 BMI 18.5 - 25 BMI 25 - 30 BMI > =30 Total
N = 44 N = 294 N = 113 N = 32 N = 483
Age at diagnosis      
  Median(IQR) 64.3 (55.4, 73.6) 67.1 (58.9, 74.2) 66.6 (58.8, 74.1) 63.7 (58.2, 67.2) 66.4 (58.6, 74)
Sex      
  Female 24 (54.5) 135 (45.9) 36 (31.9) 13 (40.6) 208 (43.1)
  Male 20 (45.5) 159 (54.1) 77 (68.1) 19 (59.4) 275 (56.9)
ECOG at diagnosis      
  ECOG > =2 9 (20.5) 64 (21.8) 27 (23.9) 5 (15.6) 105 (21.7)
  ECOG < 2 35 (79.5) 230 (78.2) 86 (76.1) 27 (84.4) 378 (78.3)
Stage at diagnosis      
  III 8 (18.2) 58 (19.7) 22 (19.5) 3 (9.4) 91 (18.8)
  IV 36 (81.8) 236 (80.3) 91 (80.5) 29 (90.6) 392 (81.2)
CA19-9 at diagnosis      
  Median (IQR) 392.1 (53.2, 2589.8) 546.1 (66.5, 3644) 801 (134.7, 4390) 689 (207.7, 14630.7) 609.6 (84.4, 3819.8)
Diabetes at diagnosis      
  Diabetes 10 (22.7) 74 (25.2) 29 (25.7) 14 (43.8) 127 (26.3)
  No-diabetes 34 (77.3) 220 (74.8) 84 (74.3) 18 (56.2) 356 (73.7)
RTX at any therapy line      
  No-RTX 43 (97.7) 273 (92.9) 108 (95.6) 30 (93.8) 454 (94)
  RTX 1 (2.3) 21 (7.1) 5 (4.4) 2 (6.2) 29 (6)
Most frequent 1st line chemotherapies      
  Gem 28 (63.6) 173 (58.5) 68 (60.2) 17 (53.1) 286 (59.2)
  Gem + Cap 6 (13.6) 39 (13.3) 14 (12.4) 6 (18.8) 65 (13.5)
  Gem + Cis 1 (2.3) 14 (4.8) 7 (6.2) 0 (0) 22 (4.6)
  BSC 6 (13.6) 23 (7.8) 10 (8.8) 2 (6.2) 41 (8.5)
  1. All values are numbers (percentages) unless otherwise specified. Median BMI was 23 (IQR 21–25). Abbreviations: BMI body mass index in kg / [height in m]2, BSC best supportive care, Cap capecitabine, Cis cisplatin, ECOG PS Eastern Cooperative Group Performance Status, Gem gemcitabine, IQR inter quartile range, RTX radiotherapy.